Magnetic Resonance Imaging-guided Thermal Radiofrequencey Ablation of Primary Renal Cell Carcinoma, Hepatic Metastasis, and Other Sites of Solid Organ Tumor and Metastases
Kidney Cancer, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
About this trial
This is an interventional treatment trial for Kidney Cancer focused on measuring stage III renal cell cancer, stage IV renal cell cancer, recurrent renal cell cancer, unspecified adult solid tumor, protocol specific, liver metastases
Eligibility Criteria
DISEASE CHARACTERISTICS: Diagnosis of primary renal cell carcinoma, hepatic metastases, or other solid tumor meeting the following criteria: Not amenable to curative or substantial palliative therapy OR Failed chemotherapy or biological response modifier therapy OR Unlikely to benefit from conventional chemotherapy No more than 5 measurable metastatic masses in the liver No greater than 5 cm in diameter Other tumor sites allowed if location and size amenable to ablation therapy Measurable disease PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: More than 4 months Hematopoietic: Granulocyte count at least 1,000/mm^3 Hemoglobin at least 8.0 g/dL Platelet count at least 100,000/mm^3 No untreated bleeding diathesis Hepatic: PT no greater than 13.5 seconds PT/PTT normal if prior warfarin or heparin use Renal: Not specified Cardiovascular: No implanted pacemaker, incompatible aneurysm clip, or other device that would preclude magnetic resonance imaging No myocardial infarction within the past 6 weeks No unstable angina Other: Not pregnant or nursing No serious active infection PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics At least 28 days since prior biological response modifier therapy Chemotherapy: See Disease Characteristics At least 28 days since prior chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to study lesion Surgery: Not specified Other: At least 7 days since prior nonsteroidal antiinflammatory drugs or aspirin At least 1 hour since prior heparin No concurrent warfarin No concurrent investigational drugs
Sites / Locations
- Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center